Expertise in
2
conditions

Kurt Redlich

Warsaw, MZ, PL 
Expertise in
2
conditions
Warsaw, MZ, PL 

Overview

Kurt Redlich practices practicing medicine in Warsaw, Poland.

Mr. Redlich is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Arthritis, Rheumatoid Arthritis (RA), Muscle Atrophy, and Osteoporosis.

He is actively involved in clinical research, co-authoring 100 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

Warsaw, MZ, Poland
Other Locations
Wroclaw, DS, Poland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection
A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection
Enrollment Status: Completed
Publish Date: January 20, 2023
Intervention Type: Drug, Other
Study Phase: Phase 2
View 2 Less Clinical Trials

100 Total Publications

Evidence of Nuclear Geometry-Driven Anisotropic Flow in O+O and Ne+Ne Collisions at sqrt[s_{NN}]=5.36  TeV.
Evidence of Nuclear Geometry-Driven Anisotropic Flow in O+O and Ne+Ne Collisions at sqrt[s_{NN}]=5.36  TeV.
Journal: Physical review letters
Published: September 18, 2025

Frequently Asked Questions about Kurt Redlich

Is Kurt Redlich a top-rated expert for Arthritis?

MediFind is an objective health platform that identifies experts based on real-world data. Kurt Redlich is classified as an Advanced expert for Arthritis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Kurt Redlich participate in research or clinical trials?

Yes. Kurt Redlich has published 100 articles and abstracts on conditions like Arthritis. You can view a list of Kurt Redlich's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Redlich's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile